BrainRepair

Executive Summary

BrainRepair is a German biotech startup focusing on autologous cord blood stem cell therapies for pediatric brain injury. The company has received ATMP (Advanced Therapy Medicinal Product) classification from the EMA, signifying regulatory recognition of its innovative approach. Currently in Phase 1 development, BrainRepair aims to translate its proprietary stem cell platform into a treatment for neonatal hypoxic-ischemic encephalopathy and other brain injuries. The autologous nature of the therapy reduces immunogenicity risks, while cord blood stem cells offer multipotent differentiation and paracrine effects. The company holds EMA SME status, which streamlines regulatory interactions and provides fee reductions. Despite early stage, the ATMP classification and a clear unmet need in pediatric neurology position BrainRepair as a potential pioneer in regenerative medicine for children. However, the company has not disclosed financial details or clinical data publicly, and its valuation remains unestimated, reflecting the high-risk, early-phase profile typical of cell therapy developers.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 clinical trial and first data readout45% success
• TBDStrategic partnership with larger pharma or CGT manufacturer for scale-up35% success
• Q4 2026EMA PRIME or accelerated assessment designation announcement40% success